Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, a Novel Poly (ADP-Ribose) Polymerase-1 Inhibitor in First-In-Human Study of Healthy Volunteers

Clinical Therapeutics - United States

doi 10.1016/j.clinthera.2017.05.148